keyword
MENU ▼
Read by QxMD icon Read
search

overall survival breast cancer

keyword
https://www.readbyqxmd.com/read/27933405/current-challenges-of-metastatic-breast-cancer
#1
Bora Lim, Gabriel N Hortobagyi
Metastasis is one of the most characteristic yet problematic behaviors of cancer cells. Stage IV breast cancer accounts for a large portion of breast cancer-related morbidity and mortality. Despite early detection and improvement in survival owing to advancements in biomedical research and overall improvement of the health system, 6-10% of patients present with stage IV disease in the developed world, with a higher incidence noted elsewhere. Despite advances in biomedical research into cancer, up to 70-80% of patients with stage IV breast cancer die of cancer in 5 years, a disproportionally higher mortality compared with non-metastatic breast cancer...
December 8, 2016: Cancer Metastasis Reviews
https://www.readbyqxmd.com/read/27933394/men-and-women-show-similar-survival-rates-after-breast-cancer
#2
Paulo Franscisco Mascarenhas Bender, Letícia Lima de Oliveira, Célia Regina Costa, Suzana Sales de Aguiar, Anke Bergmann, Luiz Claudio Santos Thuler
PURPOSE: To compare the disease-free survival (DFS) and overall survival (OS) rates of men and women undergoing treatment for breast cancer. METHODS: A retrospective cohort study of patients with breast cancer diagnosed and treated at the Cancer Hospital III of the National Cancer Institute of Brazil, Rio de Janeiro, Brazil, between 1999 and 2013. Male breast cancer cases were matched for age, year of diagnosis, and clinical staging to three female cases (1:3). Patient characteristics were abstracted from hospital records and medical charts...
December 8, 2016: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/27931285/neoadjuvant-chemotherapy-in-triple-negative-breast-cancer-an-observational-study
#3
Zhiying Shao, Shalini Chaudhri, Meng Guo, Longzhen Zhang, Daniel Rea
Triple negative breast cancer (TNBC) is a phenotype of breast cancer with aggressive clinical behavior. Because of the absence of optimal treatment, the prognosis of this disease is poor. The main purpose of this study was to detect the response to neoadjuvant chemotherapy (NACT) in a TNBC cohort and compare the long-term survival between patients with and without pathological complete response (pCR). A total of 53 patients diagnosed with TNBC from 2005 to 2013 who received NACT at the University Hospital Birmingham were enrolled in this study...
May 2016: Oncology Research
https://www.readbyqxmd.com/read/27930583/diabetes-mellitus-and-prognosis-in-women-with-breast-cancer-a-systematic-review-and-meta-analysis
#4
Xiao-Bo Zhao, Guo-Sheng Ren
BACKGROUND: Diabetes mellitus is associated with an increased risk of breast cancer, but studies of the effects of diabetes on the prognosis of women with breast cancer have yielded inconsistent findings. The present meta-analysis aimed to investigate the impact of preexisting diabetes on the prognosis in terms of overall survival (OS), disease-free survival (DFS), and relapse-free period (RFP) in women with breast cancer. METHODS: We searched the Embase and PubMed databases until June 2016 for cohort or case-control studies assessing the impact of diabetes on the prognosis of women with breast cancer...
December 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27929800/harnessing-benefit-from-targeting-tumor-associated-carbohydrate-antigens
#5
Thomas Kieber-Emmons, Bejatohlah Monzavi-Karbassi, Laura F Hutchins, Angela Pennisi, Issam Makhoul
Integrating additive or synergistic antitumor effects that focus on distinct elements of tumor biology are the most rational strategies for cancer treatment. Treatments for breast cancer have increased overall survival, but remain limited by lack of efficacy in a subset of breast cancer patients. The real challenge is to define what elements of tumor biology make the most sense to be integrated. An emerging strategy is to consider a systems biology approach to impact multiple interactions in networks as compared to hitting a specific protein-protein interaction target...
December 8, 2016: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27927689/s100a4-elevation-empowers-expression-of-metastasis-effector-molecules-in-human-breast-cancer
#6
Thamir M M Ismail, Daimark Bennett, Angela M Platt-Higgins, Morteta Al-Medhtiy, Roger Barraclough, Philip S Rudland
Many human glandular cancers metastasize along nerve tracts, but the mechanisms involved are generally poorly understood. The calcium-binding protein S100A4 is expressed at elevated levels in human cancers where it has been linked to increased invasion and metastasis. Here we report genetic studies in a Drosophila model to define S100A4 effector functions that mediate metastatic dissemination of mutant Ras-induced tumors in the developing nervous system. In flies overexpressing mutant RasVal12 and S100A4, there was a significant increase in activation of the stress kinase JNK and production of the matrix metalloproteinase MMP1...
November 10, 2016: Cancer Research
https://www.readbyqxmd.com/read/27926932/epsin-family-member-3-and-ribosome-related-genes-are-associated-with-late-metastasis-in-estrogen-receptor-positive-breast-cancer-and-long-term-survival-in-non-small-cell-lung-cancer-using-a-genome-wide-identification-and-validation-strategy
#7
Birte Hellwig, Katrin Madjar, Karolina Edlund, Rosemarie Marchan, Cristina Cadenas, Anne-Sophie Heimes, Katrin Almstedt, Antje Lebrecht, Isabel Sicking, Marco J Battista, Patrick Micke, Marcus Schmidt, Jan G Hengstler, Jörg Rahnenführer
BACKGROUND: In breast cancer, gene signatures that predict the risk of metastasis after surgical tumor resection are mainly indicative of early events. The purpose of this study was to identify genes linked to metastatic recurrence more than three years after surgery. METHODS: Affymetrix HG U133A and Plus 2.0 array datasets with information on metastasis-free, disease-free or overall survival were accessed via public repositories. Time restricted Cox regression models were used to identify genes associated with metastasis during or after the first three years post-surgery (early- and late-type genes)...
2016: PloS One
https://www.readbyqxmd.com/read/27926499/breast-carcinoma-in-situ-an-observational-study-of-tumor-subtype-treatment-and-outcomes
#8
Qi Wu, Juanjuan Li, Si Sun, Shan Zhu, Chuang Chen, Juan Wu, Qian Liu, Wen Wei, Shengrong Sun
BACKGROUND & AIMS: To evaluate the clinical presentation, treatment and outcome of patients with breast carcinoma in situ (BCIS) with special emphasis on the role of the tumor subtype and local treatment in these patients. METHODS: Using data obtained by the Surveillance, Epidemiology, and End Results (SEER) program from 2010-2013, a retrospective, population-based cohort study was conducted to investigate tumor subtype-specific differences in various characteristics, overall survival (OS) and breast cancer-specific mortality (BCSM)...
December 2, 2016: Oncotarget
https://www.readbyqxmd.com/read/27925176/pd-l1-expression-of-the-residual-tumor-serves-as-a-prognostic-marker-in-local-advanced-breast-cancer-after-neoadjuvant-chemotherapy
#9
Sheng Chen, Ruo-Xi Wang, Yin Liu, Wen-Tao Yang, Zhi-Ming Shao
This study sought to investigate the prevalence of programmed death ligand 1 (PD-L1) and its prognostic value in patients with residual tumors after neoadjuvant chemotherapy (NCT) for locally advanced breast cancer (LABC). A total of 309 patients considered as non-pathological complete responders (non-pCR) after NCT followed by mastectomy were selected. The expression of PD-L1 and tumor-infiltrating lymphocytes (TILs) in residual breast cancer cells was assessed by immunohistochemistry in surgical specimens...
December 7, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27923830/a-myc-activity-signature-predicts-poor-clinical-outcomes-in-myc-associated-cancers
#10
MoonSun Jung, Amanda J Russell, Bing Liu, Joshy George, Pei Yan Liu, Tao Liu, Anna DeFazio, David D L Bowtell, Andre Oberthuer, Wendy B London, Jamie I Fletcher, Michelle Haber, Murray D Norris, Michelle J Henderson
Myc transcriptional activity is frequently deregulated in human cancers, but a Myc-driven gene signature with prognostic ability across multiple tumor types remains lacking. Here we selected 18 Myc-regulated genes from published studies of Myc family targets in epithelial ovarian cancer (EOC) and neuroblastoma. A Myc family activity score derived from the 18 genes was correlated to MYC/MYCN/MYCL1 expression in a panel of 35 cancer cell lines. The prognostic ability of this signature was evaluated in neuroblastoma, medulloblastoma, diffuse large B-cell lymphoma (DLBCL), and EOC microarray gene expression datasets using Kaplan-Meier and multivariate Cox-regression analyses, and was further validated in 42 primary neuroblastomas using qPCR...
December 6, 2016: Cancer Research
https://www.readbyqxmd.com/read/27923045/tumor-evolution-in-two-patients-with-basal-like-breast-cancer-a-retrospective-genomics-study-of-multiple-metastases
#11
Katherine A Hoadley, Marni B Siegel, Krishna L Kanchi, Christopher A Miller, Li Ding, Wei Zhao, Xiaping He, Joel S Parker, Michael C Wendl, Robert S Fulton, Ryan T Demeter, Richard K Wilson, Lisa A Carey, Charles M Perou, Elaine R Mardis
BACKGROUND: Metastasis is the main cause of cancer patient deaths and remains a poorly characterized process. It is still unclear when in tumor progression the ability to metastasize arises and whether this ability is inherent to the primary tumor or is acquired well after primary tumor formation. Next-generation sequencing and analytical methods to define clonal heterogeneity provide a means for identifying genetic events and the temporal relationships between these events in the primary and metastatic tumors within an individual...
December 2016: PLoS Medicine
https://www.readbyqxmd.com/read/27923043/clonal-evolutionary-analysis-during-her2-blockade-in-her2-positive-inflammatory-breast-cancer-a-phase-ii-open-label-clinical-trial-of-afatinib-vinorelbine
#12
Gerald Goh, Ramona Schmid, Kelly Guiver, Wichit Arpornwirat, Imjai Chitapanarux, Vinod Ganju, Seock-Ah Im, Sung-Bae Kim, Arunee Dechaphunkul, Jedzada Maneechavakajorn, Neil Spector, Thomas Yau, Mehdi Afrit, Slim Ben Ahmed, Stephen R Johnston, Neil Gibson, Martina Uttenreuther-Fischer, Javier Herrero, Charles Swanton
BACKGROUND: Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov NCT01325428) to investigate the efficacy and safety of afatinib, an irreversible ErbB family inhibitor, alone and in combination with vinorelbine in patients with HER2-positive IBC. This trial included prospectively planned exome analysis before and after afatinib monotherapy...
December 2016: PLoS Medicine
https://www.readbyqxmd.com/read/27920689/intrathecal-methotrexate-and-craniospinal-radiotherapy-can-be-an-effective-treatment-of-carcinomatous-meningitis-in-patients-with-breast-cancer-case-reports
#13
Magdalena Meissner, Alfredo Addeo
INTRODUCTION: Carcinomatous meningitis in breast cancer occurs as a complication in up to 5% of all cases. It is a very devastating diagnosis, with a median patient survival of about 3 months. Treatment is very controversial, and different modalities of treatment have been used but none of them show significant benefit for overall survival. CASE REPORTS: We report 2 cases of carcinomatous meningitis in breast cancer patients. They received a similar treatment of a combination of intrathecal (IT) methotrexate followed by craniospinal radiotherapy...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27920688/complete-and-sustained-response-with-a-doublet-chemotherapy-protocol-in-an-81-year-old-patient-with-metastatic-breast-cancer
#14
Taynah Cascaes Puty, Gabriel S A Brito, Mariana S Dias, Henrique C Miranda, Juliana R Chaves, Heryvelton L Freitas, Luís E W Carvalho
Metastatic breast cancer (MBC) entails an overall 5-year survival of approximately 25%. The choice of therapy is influenced by expression of the HER2 gene and hormone receptors, by a disease-free interval, and by age. The use of paclitaxel combined with gemcitabine (doublet protocol) has shown efficacy as first-line treatment for MBC in either initial or maintenance therapy when compared to monotherapy with paclitaxel. There is evidence showing that the doublet protocol is a good alternative to maintenance therapy in women under 50 years old...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27920624/neoadjuvant-chemotherapy-with-docetaxel-carboplatin-and-weekly-trastuzumab-is-active-in-her2-positive-early-breast-cancer-results-after-a-median-follow-up-of-over-4-years
#15
Hans-Christian Kolberg, Leyla Akpolat-Basci, Miltiades Stephanou, Bahriye Aktas, Carla Verena Hannig, Cornelia Liedtke
INTRODUCTION: Most patients with HER2-positive breast cancer receive chemotherapy and trastuzumab. Data from adjuvant trials have shown that the combination of docetaxel, carboplatin and weekly trastuzumab (TCH) is well tolerated and as effective as anthracycline-containing regimes. Previous investigations on neoadjuvant treatment with taxanes, platinum salts and trastuzumab showed pathological complete remission (pCR) rates between 43.3 and 76%. To date, the longest published follow-up in this indication is 3 years...
October 2016: Breast Care
https://www.readbyqxmd.com/read/27919965/bevacizumab-combined-with-docetaxel-or-paclitaxel-as-first-line-treatment-of-her2-negative-metastatic-breast-cancer
#16
Leena Tiainen, Minna Tanner, Outi Lahdenperä, Pia Vihinen, Arja Jukkola, Peeter Karihtala, Niina Paunu, Teppo Huttunen, Pirkko-Liisa Kellokumpu-Lehtinen
AIM: The study evaluated the efficacy of bevacizumab combined with a taxane-based treatment for advanced breast cancer. PATIENTS AND METHODS: In this non-randomized phase II study 65 patients received 10 mg/kg bevacizumab i.v. (days 1 and 15, q4w) plus either 50 mg/m(2) docetaxel (days 1 and 15, q4w) or 90 mg/m(2) paclitaxel (days 1,8 and 15, q4w) i.v. until disease progression, maximal response, unacceptable toxicity or the withdrawal of consent. Patients without progression continued bevacizumab at 15 mg/kg i...
December 2016: Anticancer Research
https://www.readbyqxmd.com/read/27918780/effect-of-a-proposed-trastuzumab-biosimilar-compared-with-trastuzumab-on-overall-response-rate-in-patients-with-erbb2-her2-positive-metastatic-breast-cancer-a-randomized-clinical-trial
#17
Hope S Rugo, Abhijit Barve, Cornelius F Waller, Miguel Hernandez-Bronchud, Jay Herson, Jinyu Yuan, Rajiv Sharma, Mark Baczkowski, Mudgal Kothekar, Subramanian Loganathan, Alexey Manikhas, Igor Bondarenko, Guzel Mukhametshina, Gia Nemsadze, Joseph D Parra, Maria Luisa T Abesamis-Tiambeng, Kakhaber Baramidze, Charuwan Akewanlop, Ihor Vynnychenko, Virote Sriuranpong, Gopichand Mamillapalli, Sirshendu Ray, Eduardo P Yanez Ruiz, Eduardo Pennella
Importance: Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy significantly improves outcome in patients with ERBB2 (HER2)-positive metastatic breast cancer; a clinically effective biosimilar may help increase access to this therapy. Objective: To compare the overall response rate and assess the safety of a proposed trastuzumab biosimilar plus a taxane or trastuzumab plus a taxane in patients without prior treatment for ERBB2-positive metastatic breast cancer...
December 1, 2016: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/27918777/global-regional-and-national-cancer-incidence-mortality-years-of-life-lost-years-lived-with-disability-and-disability-adjusted-life-years-for-32-cancer-groups-1990-to-2015-a-systematic-analysis-for-the-global-burden-of-disease-study
#18
Christina Fitzmaurice, Christine Allen, Ryan M Barber, Lars Barregard, Zulfiqar A Bhutta, Hermann Brenner, Daniel J Dicker, Odgerel Chimed-Orchir, Rakhi Dandona, Lalit Dandona, Tom Fleming, Mohammad H Forouzanfar, Jamie Hancock, Roderick J Hay, Rachel Hunter-Merrill, Chantal Huynh, H Dean Hosgood, Catherine O Johnson, Jost B Jonas, Jagdish Khubchandani, G Anil Kumar, Michael Kutz, Qing Lan, Heidi J Larson, Xiaofeng Liang, Stephen S Lim, Alan D Lopez, Michael F MacIntyre, Laurie Marczak, Neal Marquez, Ali H Mokdad, Christine Pinho, Farshad Pourmalek, Joshua A Salomon, Juan Ramon Sanabria, Logan Sandar, Benn Sartorius, Stephen M Schwartz, Katya A Shackelford, Kenji Shibuya, Jeff Stanaway, Caitlyn Steiner, Jiandong Sun, Ken Takahashi, Stein Emil Vollset, Theo Vos, Joseph A Wagner, Haidong Wang, Ronny Westerman, Hajo Zeeb, Leo Zoeckler, Foad Abd-Allah, Muktar Beshir Ahmed, Samer Alabed, Noore K Alam, Saleh Fahed Aldhahri, Girma Alem, Mulubirhan Assefa Alemayohu, Raghib Ali, Rajaa Al-Raddadi, Azmeraw Amare, Yaw Amoako, Al Artaman, Hamid Asayesh, Niguse Atnafu, Ashish Awasthi, Huda Ba Saleem, Aleksandra Barac, Neeraj Bedi, Isabela Bensenor, Adugnaw Berhane, Eduardo Bernabé, Balem Betsu, Agnes Binagwaho, Dube Boneya, Ismael Campos-Nonato, Carlos Castañeda-Orjuela, Ferrán Catalá-López, Peggy Chiang, Chioma Chibueze, Abdulaal Chitheer, Jee-Young Choi, Benjamin Cowie, Solomon Damtew, José das Neves, Suhojit Dey, Samath Dharmaratne, Preet Dhillon, Eric Ding, Tim Driscoll, Donatus Ekwueme, Aman Yesuf Endries, Maryam Farvid, Farshad Farzadfar, Joao Fernandes, Florian Fischer, Tsegaye Tewelde G/Hiwot, Alemseged Gebru, Sameer Gopalani, Alemayehu Hailu, Masako Horino, Nobuyuki Horita, Abdullatif Husseini, Inge Huybrechts, Manami Inoue, Farhad Islami, Mihajlo Jakovljevic, Spencer James, Mehdi Javanbakht, Sun Ha Jee, Amir Kasaeian, Muktar Sano Kedir, Yousef S Khader, Young-Ho Khang, Daniel Kim, James Leigh, Shai Linn, Raimundas Lunevicius, Hassan Magdy Abd El Razek, Reza Malekzadeh, Deborah Carvalho Malta, Wagner Marcenes, Desalegn Markos, Yohannes A Melaku, Kidanu G Meles, Walter Mendoza, Desalegn Tadese Mengiste, Tuomo J Meretoja, Ted R Miller, Karzan Abdulmuhsin Mohammad, Alireza Mohammadi, Shafiu Mohammed, Maziar Moradi-Lakeh, Gabriele Nagel, Devina Nand, Quyen Le Nguyen, Sandra Nolte, Felix A Ogbo, Kelechi E Oladimeji, Eyal Oren, Mahesh Pa, Eun-Kee Park, David M Pereira, Dietrich Plass, Mostafa Qorbani, Amir Radfar, Anwar Rafay, Mahfuzar Rahman, Saleem M Rana, Kjetil Søreide, Maheswar Satpathy, Monika Sawhney, Sadaf G Sepanlou, Masood Ali Shaikh, Jun She, Ivy Shiue, Hirbo Roba Shore, Mark G Shrime, Samuel So, Samir Soneji, Vasiliki Stathopoulou, Konstantinos Stroumpoulis, Muawiyyah Babale Sufiyan, Bryan L Sykes, Rafael Tabarés-Seisdedos, Fentaw Tadese, Bemnet Amare Tedla, Gizachew Assefa Tessema, J S Thakur, Bach Xuan Tran, Kingsley Nnanna Ukwaja, Benjamin S Chudi Uzochukwu, Vasiliy Victorovich Vlassov, Elisabete Weiderpass, Mamo Wubshet Terefe, Henock Gebremedhin Yebyo, Hassen Hamid Yimam, Naohiro Yonemoto, Mustafa Z Younis, Chuanhua Yu, Zoubida Zaidi, Maysaa El Sayed Zaki, Zerihun Menlkalew Zenebe, Christopher J L Murray, Mohsen Naghavi
Importance: Cancer is the second leading cause of death worldwide. Current estimates on the burden of cancer are needed for cancer control planning. Objective: To estimate mortality, incidence, years lived with disability (YLDs), years of life lost (YLLs), and disability-adjusted life-years (DALYs) for 32 cancers in 195 countries and territories from 1990 to 2015. Evidence Review: Cancer mortality was estimated using vital registration system data, cancer registry incidence data (transformed to mortality estimates using separately estimated mortality to incidence [MI] ratios), and verbal autopsy data...
December 3, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27917036/challenging-perceptions-about-oncology-product-pricing-in-breast-and-colorectal-cancer
#19
Anthony Barron, Tim Wilsdon
Although significant progress has been made in the past decade in the treatment of both common and rare cancers, there has been significant concerns about the cost, and especially the value, of certain new oncology drugs. These concerns touch upon a number of issues regarding the price of these medicines, the value they deliver and the ability of healthcare systems to fund them. This paper looks at these perceptions and the extent to which they apply across different oncology products. Whilst it is acknowledged there is evidence that the launch price of pharmaceutical treatments for some forms of cancer has been rising in recent years, this is not uniformly the case; we find evidence to the contrary for some forms of cancer...
2016: Pharmaceutical Medicine
https://www.readbyqxmd.com/read/27916314/intraoperative-ultrasound-guidance-in-breast-conserving-surgery-shows-superiority-in-oncological-outcome-long-term-cosmetic-and-patient-reported-outcomes-final-outcomes-of-a-randomized-controlled-trial-cobalt
#20
J H Volders, M H Haloua, N M A Krekel, V L Negenborn, R H E Kolk, A M F Lopes Cardozo, A M Bosch, L M de Widt-Levert, H van der Veen, H Rijna, A H M Taets van Amerongen, K Jóźwiak, S Meijer, M P van den Tol
BACKGROUND: The multicenter randomized controlled COBALT trial demonstrated that ultrasound-guided breast-conserving surgery (USS) results in a significant reduction of margin involvement (3.1% vs. 13%) and excision volumes compared to palpation-guided surgery (PGS). The aim of the present study was to determine long term oncological and patient-reported outcomes including quality of life (QoL), together with their progress over time. METHODS: 134 patients with T1-T2 breast cancer were randomized to USS (N = 65) or PGS (N = 69)...
November 23, 2016: European Journal of Surgical Oncology
keyword
keyword
107111
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"